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Available online 5 May 2016AbstractInflammation in central nervous system (CNS) is one of the most severe diseases, and also plays an impellent role in some neurodegenerative
diseases. Glutamate (Glu) has been considered relevant to the pathogenesis of neuroinflammation. In order to diagnose neuroinflammation
incipiently and precisely, we review the pathobiological events in the early stages of neuroinflammation, the interactions between Glu and
neuroinflammation, and two kinds of magnetic resonance techniques of imaging Glu (chemical exchange saturation transfer and magnetic
resonance spectroscopy).
© 2016 Beijing You’an Hospital affiliated to Capital Medical University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Glutamate; GluCEST; 1H-MRS; Microglia; Neuroinflammation1. Introduction
As we know, an efficient immune response is required for
the defense against invading pathogens. However, neuro-
inflammation is considered a challenging clinical problem
with substantial case fatality rates [1]. An inflammatory
response in the CNS may contribute to a great number of acute
or chronic neurological diseases (for example, multiple scle-
rosis (MS), Alzheimer's disease (AD), Parkinson's disease
(PD), epilepsy). Moreover, it is also thought to be closely
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derscore the significance of the early detection of
neuroinflammation.
The pathogenesis of neuroinflammation is characterized by
a cascade of pathobiological events. Though histological
analysis after biopsy can give us a precise picture at the actual
stage of inflammation within a relatively small lesion area,
molecular imaging shows us its great potentiality in diag-
nosing the lesion development in time and space.
What distinguished molecular imaging from high
achievers, apart from assessing the accurate pathobiological
event in vivo, was its high specificity and resolution. Molec-
ular imaging referred in this review comprises the techniques
that explore the magnetic resonance properties of protons,
including amide and hydroxyl protons. It is undeniable that
PET make a great contribution to achieving the possibility to
visualize and study some neurotransmitters or their trans-
porters under physiologic and pathologic conditions, like
metabotropic Glu receptor subtype 5 [3], but it is restricted by
its radiation exposure, low resolution and imaging logistics. In
this review, we focus on a relatively new approach, namely. Production and hosting by Elsevier B.V. This is an open access article under
Fig. 1. Activated microglia release L-Glu. 2. The extracellular L-Glu causes
the elevation of astrocytic intracellular L-Glu. 3. The GLAST expression is
downregulated by the elevation of astrocytic intracellular L-Glu. 4. The
interaction between activated microglia and astrocytes in the early stages of
neuroinflammation results in evaluating the extracellular glutamate concen-
trations [10].
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one, proton magnetic resonance spectroscopy (1H-MRS).
CEST is a modern MRI technique contributes to detect the
slow-to-intermediate exchange rate of protons associated with
proteins and neurochemicals with water. 1H-MRS has been
used in clinical studies for many years, which estimates the
concentrations of molecules that contain different numbers of
protons.
In this review, we demonstrate the interaction between
activated microglia and astrocytes in the early stages of neu-
roinflammation and summarize the insights provided by 1H-
MRS and CEST. Experimental (preclinical) studies and clin-
ical applications (when available) are reviewed to emphasize
the contributions of H-MRS and CEST in understanding the
pathogenesis in the early stages of neuroinflammation. We aim
at showing the feasibility of 1H-MRS and CEST in assisting
understanding the pathophysiology and evolution in the early
stages of neuroinflammation.
2. Pathobiological events in the early stages of
neuroinflammation
The central nervous system (CNS) is composed of neurons
and the following three types of glial cells: microglia, astro-
cytes and oligodendrocytes [4]. Microglia are the primordial
innate immune cells primarily activated in response to in-
flammatory stimulation in the CNS [5,6]. Microglia exist in at
least two functionally discernable states once “activated” by
inflammation, namely a phagocytic phenotype (innate activa-
tion) or an antigen presenting phenotype (adaptive activation)
[7]. Once activated by certain pathogens, microglia secrets
numerous glutamate [8e10] and other pro-inflammatory
innate cytokines, characterized by pro-inflammatory cytokine
production and adaptive activation of T cells. Experimental
studies have shown that astrocytes may be colluded with by
the activated microglia to cause the elevation of extracellular
Glu in the early stages of neuroinflammation [10]. There are
some Glu transporters in astrocytes, like GLAST (EAAT1 in
humans) and GLT-1 (EAAT2), which are the major functional
Glu transporters, playing an important role in maintaining
extracellular Glu concentrations in the CNS below glutamate
excitotoxic levels [11].
Glu is the major free amino acid present in the brain and has
been regarded as one of the most important excitatory neuro-
transmitters in CNS. The central role of Glu in learning,memory
andmany other ways have been well reported [12,13]. However,
glutamate excitotoxicity, caused by the elevated extracellular
Glu concentration, has been reported in in vivo and in vitro
inflammation models which suggest that concentrations of Glu
increase in a range of neurologic disorders associated with
inflammation, for example, multiple sclerosis (MS) [14e17],
amyotrophic lateral sclerosis (ALS) [18] and epilepsy [19e21].
Meanwhile, impairments of Glu transporter function also have
been reported in a large number of neurological diseases asso-
ciated with inflammation [18e24].
Microglia, astrocytes and Glu play important roles in the
early stages of neuroinflammation. Preclinical studies show usthat in the early stages of neuroinflammation, activated
microglia release Glu voluntarily to trigger the elevation of
extracellular Glu, and astrocyte Glu transporters will be
downregulated causing the elevation of astrocytic intracellular
Glu levels. And as a result of these events, the extracellular
Glu will increase to a great extent (Fig. 1) [10]. So that we
draw a conclusion that extracellular glutamate concentrations
rise as a result of the interaction between activated microglia
and astrocytes in the early stages of neuroinflammation.
3. Insights provided by 1H-MRS and CEST3.1. 1H-MRSProton magnetic resonance spectroscopy (1H-MRS) is
adept in analyzing the information of spin density, spinespin
couplings, molecular tumbling and properties related to the
chemical environment of the proton. The present development
of 1H-MRS has enabled the invivo study of certain chemical
compounds or metabolites, which reflect a variety of patho-
logical processes. Based on this, 1H-MRS has been widely
used in studying the physiological or pathological changes in
brain which are associated with inflammation during diseases
progression [25e32]. For example, dedicated editing 1H-MRS
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separating it from the strongly overlapping glutamine signal.
Short echo times along with spectral editing techniques will be
valuable for 1H-MRS in detecting Glu's signature groups
[33,34].
Clinical studies showed that Glu concentrations (estimated
at 3 T) increased in active, enhancing lesions, and remained
normal by contrast in chronic lesions, in multiple sclerosis,
infiltrated by inflammation (Fig. 2) [35]. Other experimental
studies suggest that increased inflammation probably is related
to the Glu in active lesions, because active MS lesions show
high glutaminase expression (glutaminase is a marker of Glu
production) in microglia, linked cheek by jowl to the dystro-
phic axons [36]. And in the brain, previous work has shown
higher Glu content in gray matter than white matter [37,38].
Therefore, studies of Glu in vivo will make the changes of this
neurotransmitter associated with the pathogenesis of neuro-
inflammation identifiable. And it seems valuable to detect the
changes of Glu's concentrations by 1H-MRS to alarm us that
the inflammation has begun to infiltrate CNS.
Unfortunately, sometimes some clinical studies fall short of
expectations. At 1.5 T, with different protocols and patients
with different characteristics, other clinical studies show
different results. Productive changes in Glu concentrations
were reported neither between the normal-appearing white
matter and control white matter, nor between the gray matter
of patients with MS and that of healthy controls [38]. These
negative studies can be attributed to the low extracellular
concentration of Glu (0.1e1 mmol/L) [9], and low magnetic
field which struggled with a lack of internal capability in its
resolving power efforts. What is more, though 1H-MRS has
been widely used to monitor the Glu changes in diseases
associated with inflammation (for example, MS, AD, PD, etc)
[1], it is criticized because of poor spatial resolution and long
acquisition time. In a word, the blemishes of 1H-MRS make itFig. 2. Glutamate concentrations in multiple sclerosis. Glutamate concentrations
healthy controls. (A) Chemical-shift imaging using echo time (TE)-average point
highlight glutamate signal; warmer colors show higher glutamate concentrations, w
glutamate concentrations between all patients with multiple sclerosis, each m
SPMS ¼ secondary-progressive multiple sclerosis. RRMS ¼ relapsing-remitting mparticularly difficult to map the differences of Glu between
gray and white matter in brain intuitively.
Therefore, a high spatial resolution imaging is requisite to
spatially map Glu to assist understanding the pathophysiology
and evolution in the early stages of neuroinflammation.3.2. CESTSince the amount of protons in tissue metabolites (like Glu)
is much smaller than that of water protons, when 1H-MRS is
applied to living tissue to obtain noninvasive biochemical in-
formation on small and mobile metabolites (for example, the
concentration of Glu) and physiological parameters, it is
strongly limited in terms of signal-to-noise ratio (SNR), spatial
resolution and scanning time in vivo. Sherry AD et al. [39]
applied chemical exchange saturation transfer (CEST)
contrast agents for magnetic resonance imaging to augment
the dependence of the exchange rates on physical and physi-
ological parameters that characterize the microenvironment
such as metabolite concentration, restriction in motion, tem-
perature, and pH.
Recently, it is reported that pH in liver [40], glycosami-
noglycan in cartilage [41], gene expression [42], and myo-
inositol in brain [43] can be detected by CEST, which is
associated with amide and hydroxyl protons from different
amino acids, proteins and other molecules. Besides, recent
studies showed that at the asymmetric magnetization transfer
ratio (MTRasymmetry) of 3 ppm, we could find a large fraction
of Glu signal, with the relative amount depending on the
saturation power used [44]. We used 3 ppm as the GluCEST
resonance saturation frequency, and our phantom studies at
7.0T (Fig. 3) demonstrated a similar result that the GluCEST
effect depends on different concentrations compared with the
studies in Philadelphia [44]. In brain, in-vivo human GluCEST
maps showed a similar distribution pattern of Glu compared(mmol/L) in the white matter are shown, with differences between patients and
resolved spectroscopy (PRESS) at 3T, which is an editing technique used to
hereas cooler colors show lower metabolite concentrations. (B) Differences in
ultiple sclerosis group, and healthy controls. MS ¼ multiple sclerosis.
ultiple sclerosis. CIS ¼ clinically isolated syndrome [35].
Fig. 3. GluCEST images at 7T of a phantom consisting of test tubes with different concentrations of L-Glu solutions (pH 7.0) immersed in a beaker containing
PBS. All the experiments were performed at 37 C.
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(Fig. 4) [44], which is higher in gray matter compared to white
matter [44]. Early applications of GluCEST to animal models
of Alzheimer's disease have been reported, which showed a
decrease in GluCEST contrast in age-matched transgenic
mouse model of Alzheimer's disease (AD) (APP-PS1) relative
to wild-type (WT) mouse brain (Fig. 5) [45]. Thanks to these
preclinical studies and clinical applications, detecting theFig. 4.GluCEST imaging from a healthy human brain acquired at 7T (A) B1 an
in percentage) (B) Map of distribution volumes (DVs) of metabotropic Glu recept
Fig. 5. Glutamate chemical exchange saturation transfer (GluCEST) mapping
Alzheimer's Disease (AD) (APP-PS1) (B). (A)The corresponding GluCEST map o
the decreased GluCEST contrast compared with the wild-type (WT) [45].changes in Glu concentration is becoming increasingly
practicable.
Though GluCEST has begun to be translated from experi-
mental studies to patient studies, it is still a relatively imma-
ture imaging technique so far, and there are lots of problems
remained, like the phenomenon of intermediate to fast ex-
change (k Du) which mediates the maximum of asymmetry
plot occurred at 1.2 ppm, but not 3.00 ppm at pH 7, and thed B0 corrected GluCEST contrast map (Color bar represents GluCEST contrast
or subtype 5 from a PET image [2,44].
of wild-type (WT) mouse (A) and age-matched transgenic mouse model of
f WT mouse. (B)The corresponding GluCEST map of APP-PS1, which shows
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indeterminated. Despite of these limitations, based on abun-
dant theories and data from preclinical or clinical studies,
GluCEST has possessed its glamour of mapping relative
changes of Glu concentration.
4. Conclusions
Neuroinflammation is associated with lots of notorious
diseases (for example, MS, AD, PD, epilepsy), so it is
important to diagnose it incipiently and precisely. Experi-
mental (preclinical) studies and clinical applications have
shown us that extracellular glutamate concentrations rise as a
result of the interaction between activated microglia and as-
trocytes in the early stages of neuroinflammation. With high
specificity and resolution, some kinds of molecular imaging,
like 1H-MRS and CEST, help to assess these events accu-
rately in vivo. 1H-MRS makes the changes in this neuro-
transmitter identifiable, and little by little, GluCEST begins to
be translated from experimental studies to patient studies.
There are some ineluctable limitations of detecting the
changes of L-Glu concentrations by 1H-MRS because of its
poor spatial resolution and long acquisition time. Though
GluCEST provides markedly increased spatial and temporal
resolution than 1H-MRS, it is still struggling to solve the
problems mentioned above. Notwithstanding these limita-
tions, GluCEST and 1H-MRS could ameliorate these issues by
efforts from everyone to apply high field MRI machines,
solve the shimming aporia, and come up with a true and
unified mechanism of correcting the B1 and B0 map. All in
all, with dramatic potential, 1H-MRS and GluCEST are
feasible of assisting understanding the pathophysiology in the
early stages of neuroinflammation.
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